Deutsche Capital participates in the A-round financing of Sinopharm Dental
At the beginning of the new year in 2021, Sinopharm Dental, a new force in China’s oral cavity integration + innovation, completed the A round of financing, Deutsche Capital participated in the investment. This round of financing will bring new vitality to Sinopharm Dental, integrate and expand the midstream channels, and create a co-construction under the Chinese DSO model. Bring more resources on the dental innovation business and the consumer side, and jointly promote the “Integration +” of Sinopharm Dental “Innovation” develops more rapidly and thoroughly realizes the transformation from a distributor to a one-stop dental service provider.
Shao Jun, the founding partner of Deutsche Capital, said: “The dental industry has a huge market space, and the industrial chain’s upgrading and integration is the general trend. Sinopharm Dental has the brand advantages and resource advantages, and the team is professional and mature with industry experience. The company is based on China’s booming growth. The oral midstream area connects the small and scattered upstream and downstream, empowering as a leading subsidiary in each region, realizing the cultural, system, and data connection and improvement, and the future is unlimited. The oral cavity is accelerating its growth and looking forward to integration + the rapid development of innovative models, and the company has formed a large industrial ecology. It will become a leading enterprise in the oral market as soon as possible, benefiting the oral health of the people!”
Wu Aimin, President of Sinopharm Capital and Chairman of Sinopharm Dental, believes: “With the improvement of the national economy and the increase in demand for health care, China’s dental market has huge room for development. In 2016, Sinopharm Capital began to conduct mergers and acquisitions in the dental field. Through the full demonstration of the industry, it finally determined the development strategy of “building a one-stop dental empowerment platform covering the entire industry chain”, which was formally established in 2017 Sinopharm Dental Corporation.”
After more than three years of incubation, Sinopharm Dental Corporation has rapidly integrated the oral cavity’s middle reaches. It has deployed 16 subsidiaries and eight second-tier subsidiaries. The distribution business of dental consumables and equipment covers all central provinces in the country. Simultaneously, on the dental innovation business side, Sinopharm Dental’s deep-growing Chinese DSO business has also achieved good pilot results. Sinopharm Dental’s DSO business provides a one-stop service for private dental clinic operations, including but not limited to supply chain finance, clinic medical engineering Design, guarantee 2B e-commerce, practicing doctors, clinic diversion, etc. Under the blueprint of building an ecological chain of oral health, Sinopharm Dental has stepped into consumer business and created a professional consumer dental brand “Ai Chi Yi”, which integrates the insurance industry, innovative payment methods, personal oral care products, dental clinics and other high-quality resources. Insurance companies, large corporate customers, employee benefits, point currency exchange, and other flow entrances provide the best choice for oral prevention, diagnosis and treatment, and daily care.
Lu Sang, Director and general manager of Sinopharm Dental, said: “Some unique characteristics of the oral industry determine the diverse business models of the midstream track. Sinopharm Dental is based on the oral cavity’s midstream and can stimulate a win-win development trend by linking up mid and downstream partners, to help the dental industry in the next golden 20 years. Since the establishment of Sinopharm Dental in 2017, the team has gradually grown. These achievements are inseparable from the strong support of Sinopharm Capital and all team members and company partners’ hard work. I want to express my heartfelt gratitude. At the same time, I would like to thank all the new investors for their recognition. After completing the financing, the company will continue to promote the oral industry model’s improvement and innovation, optimize the efficiency of the industry, increase the scale of the industry, and benefit the oral health of the Chinese people.”
